A5046731425- Cholangiocarcinoma and Gallbladder Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Brain Metastases and Treatment
- Cancer Diagnosis and Treatment
- Estrogen and related hormone effects
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Gene expression and cancer classification
- Blood groups and transfusion
- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- Effects of Vibration on Health
- Medical Imaging and Pathology Studies
- Salivary Gland Tumors Diagnosis and Treatment
- Ergonomics and Musculoskeletal Disorders
- Neuroendocrine Tumor Research Advances
- Growth Hormone and Insulin-like Growth Factors
- Bone health and treatments
- Genomics and Chromatin Dynamics
Gentofte Hospital
2016-2024
Copenhagen University Hospital
2018-2023
Herlev Hospital
2016-2022
University of Copenhagen
2016-2020
University of Applied Sciences Technikum Wien
2018
RMIT University
2018
Brain metastases (BM) from colorectal cancer (CRC) are rare, but the incidence is suspected to rise as treatment of metastatic (m) CRC improves. The aim this study was identify possible biological and clinical characteristics at initial presentation mCRC that could predict later risk developing BM. Furthermore, we wished estimate BM in long-term surviving patients.We conducted a retrospective on Danish multicenter cohort patients with who received cetuximab irinotecan (CetIri) third-line...
Several studies have investigated correlations between metastatic pattern and mutation status in patients with colorectal cancer (CRC). However, most of the were small heterogeneously designed further research is needed to confirm previous results. In this study, we association RAS (KRAS or NRAS), BRAF, PIK3CA mutations (m) CRC.This study reviewed Danish biobank database mCRC who received cetuximab irinotecan, independent status, after fluoropyrimidine, oxaliplatin irinotecan treatment...
Abstract Biliary tract cancer (BTC) is characterized by a desmoplastic extracellular matrix (ECM). We tested the diagnostic and prognostic use of seven circulating biomarkers ECM remodeling: pro‐peptides type III collagen (PRO‐C3), VI (PRO‐C6) XI (PRO‐C11), metalloprotease (MMP) degraded (C3M) IV (C4M) fragments, granzyme B fragments (C4G) MMP citrullinated vimentin (VICM) marker macrophage activation. The study included 269 patients with all stages BTC 49 benign biliary diseases. Serum...
Biliary tract cancer (BTC) is a rare gastrointestinal with dismal prognosis. Biomarkers clinical utility are needed. In this study, we investigated the association between survival and 89 immuno-oncology-related proteins, aim of identifying prognostic biomarkers for BTC. The study included patients BTC (n = 394) treated at three Danish hospitals. Patients were divided into four cohorts: first-line discovery cohort 202), validation 118), second-line 56), surgery 41). Plasma protein levels...
•Circulating FASLG and Gal-1 are associated with checkpoint inhibitor efficacy in patients pancreatic cancer.•Patients could be separated into inflamed cold tumor clusters based on immune activity-related circulating proteins.•Several proteins, including PD-1, CXCL9, FASLG, increased during immunotherapy but not chemotherapy. BackgroundMost ductal adenocarcinoma (PDAC) do benefit from treatment. However, the phase II study CheckPAC (NCT02866383) showed a clinical (CB) rate of 37% response...
Secreted phospholipase A2 group IIa (sPLA2-IIa) has been shown to promote tumor genesis and cell proliferation. The properties of this enzymes are utilized in liposomal drug delivery chemotherapy. sPLA2-IIa is also under investigation as a possible treatment target itself, prognostic marker. expression breast cancer not examined extensively, never using immunohistochemistry. We sought investigate the cohort advanced patients with correlation known clinicopathologic risk factors survival....
Many cyclists use online-maps for planning their routes, however, only little information is known about the road surface of different cycling paths, farm or public roads. Cyclists prefer surfaces fitting type bike they are using a specific ride (e.g., time trial, road, MTB, cyclocross, gravel bike). Often riders upload data including GPS, heart rate (HR) power (P) on platforms like Strava Garmin Connect. In this research we tried to evaluate whether it possible (1) quality 3D accelerometer...
Proximity extension assay (PEA) is a novel antibody-based proteomic technology. Sparse data have been published concerning the matrix effect of serum vs. ethylenediamine tetraacetic acid (EDTA) plasma and reproducibility results obtained using PEA technology.We analyzed samples with PEA-based 92-plex Olink® immuno-oncology (I-O) assay. To estimate effect, we paired EDTA from 12 patients biliary tract cancer. evaluate reproducibility, used 7 studies, where 6-8 pancreatic cancer were as...
Biliary tract cancer (BTC) is associated with a dismal prognosis, partly because it typically diagnosed late, highlighting the need for diagnostic biomarkers. The purpose of this project was to identify and validate multiprotein signatures that could differentiate patients BTC from non-cancer controls.In study, we included treatment-naïve BTC, healthy controls, benign conditions including biliary disease. Participants were divided into three non-overlapping cohorts: case-control-based...
Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated predictive value multigene mRNA-based drug response predictor (DRP) BC with epirubicin. The DRP is mathematical method combining vitro sensitivity gene expression clinical genetic information from > 3000 tumor samples. From DBCG cohort, 140 consecutive patients were treated epirubicin between May 1997 November 2016. After patient informed consent, mRNA was isolated...
e12056 Background: Fulvestrant is a highly selective estrogen receptor (ER) antagonist used in the treatment of postmenopausal patients with ER-positive advanced breast cancer. To identify who are sensitive to fulvestrant we applied multigene mRNA-based Drug Response Predictor (DRP) broadly validated by Wang et al1 and for Knudsen al2. The DRP based on measuring full transcriptome cell lines resistant drug compared expression patterns tumors. Methods: evaluate patients’ transcriptomes from...
e15115 Background: Recently, analyses of tumor samples from large phase III studies have demonstrated that epidermal growth factor (EGFR)-targeted monoclonal antibodies (mAbs) treatment in first-line should be limited to patients with KRAS and NRAS exons 2, 3 4 wild-type (wt) tumors. Since only data exist on receiving later-line EGFR-targeted therapy outcome relation RAS status, we analyzed the mutational status BRAF 480 cetuximab irinotecan. All were prior treated a fluoropyrimidine,...
1071 Background: Epirubicin remains a cornerstone in the treatment of primary and advanced breast cancer. This study evaluated predictive effect multigene mRNA-based Drug Response Predictor (DRP) cancer (ABC). We applied mathematical method combining vitro sensitivity with gene expression patterns tumors. Previously DRP has been broadly validated 1 , 2 including retrospective validation epirubicin 3 . Methods: Among 838 consecutive patients from DBCG cohort 137 were treated between May 1997...
e12532 Background: Exemestaneis a steroidal aromatase inhibitor used in the treatment of postmenopausal patients with estrogen receptor(ER)-positive adjuvant and advanced breast cancer. We aimed to determine predictive value multigene mRNA-based mathematical algorithm (Drug Response Predictor (DRP)) for benefit exemestane. The DRP is founded on measuring full cancer transcriptome sensitive drug resistant cell lines compared expression patterns tumors broadly validated several studies (Wang...
Abstract Background Even with positive oestrogen receptor (ER+) status some advanced breast cancer (ABC) patients fail to benefit from endocrine therapy (ET). A method that previously predicted other drugs in various cancers was evaluated. Here multigene markers based on aromatase inhibitor (AI) effect vitro were used for prediction of AI ER+ ABC patients. Simultaneously effects long-term ET predictive efficacy Methods The Drug Response Predictors (DRPs) are correlations between baseline...